The benefits of immunotherapy combinations. [electronic resource]
Producer: 20180517Description: S67-S69 p. digitalISSN:- 1476-4687
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- immunology
- Antigens, Neoplasm -- immunology
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Biomarkers, Tumor
- CTLA-4 Antigen -- antagonists & inhibitors
- Cancer Vaccines -- immunology
- Cell Cycle Checkpoints -- drug effects
- Clinical Trials as Topic
- Combined Modality Therapy -- adverse effects
- Drug Costs
- Humans
- Immunotherapy -- economics
- Indoleamine-Pyrrole 2,3,-Dioxygenase -- antagonists & inhibitors
- Ipilimumab -- administration & dosage
- Lung Neoplasms -- drug therapy
- Male
- Melanoma -- drug therapy
- Nivolumab
- Oncolytic Virotherapy
- Patient Selection
- Precision Medicine
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Survival Analysis
- T-Lymphocytes -- drug effects
- Tryptophan -- analogs & derivatives
- Tumor Escape -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.